Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13638
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChen, Qen
dc.contributor.authorJackson, Heather Men
dc.contributor.authorGibbs, Pen
dc.contributor.authorDavis, Ian Den
dc.contributor.authorTrapani, Joseph Aen
dc.contributor.authorCebon, Jonathan Sen
dc.date.accessioned2015-05-16T03:31:18Z
dc.date.available2015-05-16T03:31:18Z
dc.date.issued1998-12-01en
dc.identifier.citationCancer Immunology, Immunotherapy : Cii; 47(4): 191-7en
dc.identifier.govdoc9875671en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13638en
dc.description.abstractThe spontaneous cytotoxic T cell responses to melanoma differentiation antigens and influenza matrix peptide were compared in 20 HLA-A2+ melanoma patients and 17 healthy A2+ individuals. Cytotoxic T lymphocyte (CTL) responses were determined by mixed lymphocyte peptide culture (MLPC) involving two stimulations of unfractionated peripheral blood lymphocytes (PBLs) with peptide in vitro. CTL responses to Melan-A 9-mer (amino acids 27-35, AAGIGILTV) peptide were detected in 4 out of 16 normal individuals, but in none of the melanoma patients. CTL specific for influenza matrix peptide were frequently found in both normal individuals and melanoma patients, suggesting that generalized immuno-suppression was not responsible for this difference. No significant responses were observed in either normal individuals or melanoma patients to Melan-A 10-mer (26-35, EAAGIGILTV), two gp1OO epitopes (280-288, YLEPGPVTA; 457466, LLDGTATLRL) and two tyrosinase epitopes (1-9, MLLAVLYCL; 368-376, YMDGMSQV). Melan-A (27-35)-specific CTL cells generated by normal individuals and melanoma patients recognized both synthetic peptide-pulsed T2 cells and two HLA-A2+, Melan-A+ melanoma cell lines (ME272, LAR1) in an antigen-specific, MHC class I restricted manner. T cells generated against Melan-A 9-mer were also able to recognize Melan-A 10-mer-pulsed target cells. Spontaneous CTL responses to Melan-A 9-mer from three known responder normal individuals were further evaluated over a prolonged time course (6-11 months). All 3 subjects demonstrated specific Melan-A 9-mer responses throughout the study period, although lytic activity fluctuated over time for a given individual. We found the MLPC assay to be reliable and easy to perform for monitoring T cell responses, although it may still not be sufficiently sensitive to detect low numbers of precursor T cells.en
dc.language.isoenen
dc.subject.otherAdjuvants, Immunologic.pharmacologyen
dc.subject.otherAmino Acid Sequenceen
dc.subject.otherAntigens, Differentiation.immunology.pharmacologyen
dc.subject.otherAntigens, Neoplasmen
dc.subject.otherHumansen
dc.subject.otherLymphocyte Activation.drug effectsen
dc.subject.otherMART-1 Antigenen
dc.subject.otherMelanoma.immunologyen
dc.subject.otherNeoplasm Proteins.immunology.pharmacologyen
dc.subject.otherOligopeptides.immunology.pharmacologyen
dc.subject.otherT-Lymphocytes, Cytotoxic.drug effects.immunologyen
dc.titleSpontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer immunology, immunotherapy : CIIen
dc.identifier.affiliationLudwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Repat Cancer Centre, Heidelberg, Victoria, Australiaen
dc.description.pages191-7en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/9875671en
dc.type.austinJournal Articleen
local.name.researcherCebon, Jonathan S
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Feb 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.